Moderna Inc said on Monday it was advancing two vaccine candidates for the fall, one designed against the BA.1 variant of Omicron and another against the BA.4 and BA.5 subvariants.
This has been done based on different market preferences for vaccines against Omicron subvariants, the company said.
